Abbott’s New CardioMEMS™ Remote Monitoring Reader Gains FDA Approval; Mobia Medical and Sanford Health Secure FDA Approval for Vivistim Stroke Therapy; Johnson & Johnson Introduces Cereglide™ 42, Cereglide™ 57, and Innerglide™ 7 to Strengthen Catheter Portfolio; Baird Medical Advances Worldwide Registration of AI-Based Surgical Technology; THINK Surgical Achieves First Clinical Use of the TMINI Miniature Robotic System Paired With the Stryker Triathlon Knee System; Monteris Medical Reports Study Linking NeuroBlate® Laser Ablation to Stronger Immunotherapy Response in Recurrent High-Grade Brain Tumors

Abbott’s Next‑Generation Cardiomems™ Remote Heart Failure Monitoring Reader Received FDA Approval to Enhance Patient Experience and Help Detect Disease Progression 

On 27 February 2026, Abbott announced that the U.S. Food and Drug Administration (FDA) had approved the company’s CardioMEMS™ HERO device, a next-generation pulmonary artery (PA) pressure reader, to support the care of people living with heart failure. The reader featured new design elements aimed at empowering patients and clinicians with daily insights to detect and manage heart failure progression. Abbott subsequently began the commercial release of the CardioMEMS HERO reader in the United States.

Heart failure, a progressive condition in which the heart cannot circulate blood efficiently, can lead to severe complications if left untreated, including breathing difficulties, fluid accumulation in the lungs, organ damage, irregular heart rhythms, and death. At the time, approximately 6.7 million people in the United States were living with heart failure, with projections indicating this number would rise to 8.5 million by 2030.

“Abbott’s CardioMEMS HERO reader is modernizing a proven and effective remote patient management system, making it even more convenient for patients to use a device that has shown a 57% reduction in heart failure hospitalizations,” said Finn Gustafsson, M.D., Ph.D., chief medical officer and divisional vice president of Abbott’s heart failure business. “With this new reader, people can work with their doctors to proactively manage their condition outside of the doctor’s office even more efficiently – increasing convenience and the patient experience.”

As per DelveInsight’s “Cardiac Monitoring Devices Market Report,” the global cardiac monitoring devices market is expected to increase from ~USD 21,360.61 million in 2024 to ~USD 31,602.55 million by 2032, reflecting strong and sustained growth. The global cardiac monitoring devices market is growing at a CAGR of 5.11% during the forecast period from 2025 to 2032. The cardiac monitoring devices market is being primarily driven by the growing instances of cardiovascular diseases and their associated risk factors, increasing demand for remote patient monitoring, technological advancements in product designs, and an increase in product development activities among the key market players.

Mobia Medical and Sanford Health Announced the FDA Approval of Vivistim for Stroke Therapy 

On 3 February 2026, a breakthrough therapy for stroke survivors aimed at improving upper-limb function through vagus nerve stimulation (VNS) paired with rehabilitation became available at Sanford Bismarck. Mobia Medical Inc. and Sanford Health announced the availability of the FDA-approved Vivistim device.

Vivistim became the first and only FDA-approved device to use VNS during therapy, helping stroke survivors achieve significant improvements in arm and hand function even years after their stroke. Clinical studies have shown that patients using Vivistim achieved two to three times greater improvement compared to rehabilitation alone.

The system worked by delivering gentle, precisely timed vagus nerve stimulation during therapist-guided rehabilitation, strengthening neural pathways that support motor recovery. It was intended for chronic ischemic stroke survivors who continued to experience moderate to severe upper-limb impairment six months or more after their stroke. The therapy involved a small implanted device, therapist-led sessions using a wireless remote, and at-home exercises activated by a handheld magnet to support continued recovery in daily tasks. 

“Our team is excited by the potential of Vivistim,” said Tiffany Skor, MOTR/L, CLT, therapy and rehabilitation manager, Sanford Bismarck. “As occupational therapists, we see firsthand how innovation can reshape the patient journey, and Vivistim represents a significant step forward. Its capabilities open new possibilities for personalized therapy, improved outcomes, and more efficient care. We’re excited to bring this technology into our practice and are confident it will make a meaningful difference for the patients and families we serve.

As per DelveInsight’s “Implantable Neurostimulation Devices Market Report,” the implantable neurostimulation devices market was valued at $1.7 billion in 2024 and is estimated to reach $4.3 billion by 2032, exhibiting a CAGR of 9.7% from 2025 to 2032. A surge in the number of neurological disorders is expected to drive the implantable neurostimulation devices market. The increasing incidences of chronic pain, Parkinson’s disease, epilepsy, and psychiatric conditions are a major driver of the implantable neurostimulation devices market growth. With aging populations and lifestyle-related disorders on the rise globally, the demand for neurostimulation solutions has grown. Patients with conditions that are resistant to pharmacological treatments are turning to these devices for long-term relief, especially as they can improve quality of life with minimal side effects compared to conventional medications. 

On 26 February 2026, Johnson & Johnson announced the U.S. launch of the CEREGLIDE™ 42 and CEREGLIDE™ 57 aspiration catheters, along with the INNERGLIDE™ 7 delivery aid, as the latest additions to its aspiration-first stroke portfolio. These devices completed the CEREGLIDE™ family and were designed to help physicians reach and remove distal clots more consistently, while simplifying procedural decisions and supporting performance across a broad range of ischemic stroke cases.

CEREGLIDE™ 42 and CEREGLIDE™ 57 were built with a proprietary variable-stiffness construction, providing flexible distal navigation and supportive proximal control. With the launch, the CEREGLIDE™ family included 42, 57, and 71 aspiration catheters, offering a comprehensive range designed for consistent performance and compatibility across stroke intervention procedures.

“We designed this multi-axial system to address procedural challenges physicians face when treating stroke,” said Christian Cuzick, Worldwide President, Neurovascular, MedTech, Johnson & Johnson. “With this expanded portfolio, we’re simplifying decisions, enhancing consistency across device sizes, and reinforcing our commitment to helping improve patient outcomes.” 

“Accessing distal occlusions remains one of the biggest technical challenges we face, especially in smaller or more tortuous vessels,” said Ameer E. Hassan2, DO, FAHA, FSVIN, Neuroscience Institute, Valley Baptist Medical Center, Harlingen, Texas. “In my experience, CEREGLIDE 42 and 57 track reliably while maintaining strong proximal support, even over multiple passes.3 That balance of flexibility and control gives me greater confidence when performing aspiration-first thrombectomy in more complex anatomy.

As per DelveInsight’s “Acute Ischemic Stroke Treatment and Diagnosis Market Report,” the acute ischemic stroke treatment and diagnosis market was valued at USD 4,686.39 million in 2024, growing at a CAGR of 4.85% during the forecast period from 2025 to 2032 to reach USD 6,811.05 million by 2032. The increasing incidence of strokes, driven by an aging population and lifestyle changes, has heightened the demand for effective treatment options. Concurrently, the rising prevalence of risk factors such as hypertension, diabetes, and obesity has led to a greater awareness of stroke prevention and management, prompting healthcare providers to seek advanced therapeutics. Together, these factors are expected to boost consumer engagement and drive the growth of the acute ischemic stroke treatment and diagnosis market during the forecast period from 2025 to 2032.

Baird Medical Accelerated Global Registration of AI-Driven Surgical Software

On 4 March 2026, Baird Medical Investment Holdings Ltd., a leader in minimally invasive Microwave Ablation (MWA) technology, announced that it had completed the development of its cross-platform surgical software and had officially commenced the registration process in the United States, the European Union, and China. 

The digital infrastructure had been engineered to integrate directly with Baird Medical’s upcoming non-invasive and minimally invasive fully automated surgical robotic system, establishing a comprehensive, closed-loop surgical ecosystem. This ecosystem spanned pre-operative analysis and decision-making, intra-operative execution, and post-operative evaluation. The advancement accelerated the company’s commercial roadmap and addressed the growing global demand for highly integrated, intelligent interventional systems. 

According to DelveInsight’s “Surgical Robotic System Market Report”, the global surgical robotic system market size is expected to increase from USD 11,082.32 million in 2024 to USD 29,785.13 million by 2032, reflecting strong and sustained growth. The Global Surgical Robotic System Market is growing at a CAGR of 13.21% during the forecast period from 2025 to 2032. The rising incidence of chronic disorders such as cancer, cardiovascular diseases, and orthopedic conditions is significantly boosting the demand for advanced surgical interventions, thereby propelling the growth of the Surgical Robotic Systems Market. As chronic conditions often require complex, high-precision surgeries, robotic-assisted procedures offer enhanced accuracy, minimal invasiveness, and quicker recovery times, making them highly suitable for treating such ailments.

THINK Surgical Announced First Clinical Cases With the TMINI® Miniature Robotic System and the Stryker® Triathlon® Knee System 

On 27 February 2026, THINK Surgical, Inc., an innovator in orthopedic surgical robotics, announced that the first cases had been completed using the TMINI® Miniature Robotic System in combination with the Triathlon® Knee System from Stryker®.

Multiple surgeons and hospitals across the United States had performed these cases with the newly compatible implant. THINK Surgical planned to continue expanding commercialization throughout the year.

These cases marked a significant milestone for THINK Surgical, following the 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the TMINI System’s compatibility with the Stryker® Triathlon® Knee System. This approval further expanded implant options for surgeons using the TMINI System, which now includes nine different compatible implant options.

“The addition of the Triathlon® Knee System to our platform further demonstrates THINK Surgical’s commitment to open platform robotics and empowering surgeon choice,” said Stuart Simpson, CEO and President of THINK Surgical. “We believe that implant agnostic technology enables surgeons to deliver a more personalized solution for each patient, potentially leading to better clinical outcomes.”

According to DelveInsight’s ”Surgical Robotic System Market Report,” the global surgical robotic system market Size is expected to increase from USD 11,082.32 million in 2024 to USD 29,785.13 million by 2032, reflecting strong and sustained growth. The Global Surgical Robotic System Market is growing at a CAGR of 13.21% during the forecast period from 2025 to 2032. The rising incidence of chronic disorders such as cancer, cardiovascular diseases, and orthopedic conditions is significantly boosting the demand for advanced surgical interventions, thereby propelling the growth of the Surgical Robotic Systems Market. As chronic conditions often require complex, high-precision surgeries, robotic-assisted procedures offer enhanced accuracy, minimal invasiveness, and quicker recovery times, making them highly suitable for treating such ailments.

Monteris Medical Announced Study Showing Neuroblate® Laser Ablation Enhanced Immunotherapy Response and Improved Overall Survival in Recurrent High-Grade Brain Tumors 

On 4 March 2026, Monteris Medical, a leader in minimally invasive neurosurgical technology with its NeuroBlate® System, announced that a newly published randomized prospective study in Nature Communications had suggested that laser interstitial thermal therapy (LITT) using NeuroBlate could enhance the effectiveness of the immunotherapy drug pembrolizumab (Keytruda®) in patients with recurrent high-grade astrocytoma, including glioblastoma (GBM).

The findings were derived from a Phase 1/randomized Phase 2b clinical trial (NCT02311582) conducted by investigators at Washington University, the University of Florida, and the University of Southern California, which evaluated the combination of NeuroBlate LITT followed by pembrolizumab. High-grade astrocytomas, including GBM, had remained among the most aggressive and treatment-resistant brain tumors. Immune checkpoint inhibitors like pembrolizumab had historically shown limited benefit in this population due to factors such as the impermeability of the blood-brain barrier (BBB) and tumor characteristics that allowed evasion of the body’s immune response.

“What we’re seeing in this trial is that NeuroBlate may be doing more than cytoreducing the tumor – it appears to prime the immune system in ways that make pembrolizumab more effective at delivering real clinical benefit,” said Dr. David Tran, lead author and division chief, neuro-oncology, and co-director of the University of Southern California Brain Tumor Center in Los Angeles. “This opens the door to continue studying new treatment strategies for patients who currently have very limited options.” 

“Monteris has invested for more than a decade in pioneering the use of NeuroBlate for brain tumors and drug-resistant epilepsy, and we are proud that our technology continues to play a central role in advancing minimally invasive neurosurgery,” said Martin J. Emerson, president and chief executive officer of Monteris Medical. “This new clinical evidence suggests that NeuroBlate may also serve as a powerful enabler of treatments like immunotherapy. We are honored to support the innovators and institutions pushing this field forward and, most importantly, to help bring new hope to patients and their families.”

According to DelveInsight’s “Minimally Invasive Surgical Devices Market Report, the global minimally invasive surgical devices market is expected to increase from USD 30,798.01 million in 2024 to USD 53,259.85 million by 2032, reflecting strong and sustained growth. The global minimally invasive surgical devices market is growing at a CAGR of 7.13% during the forecast period from 2025 to 2032. The market of minimally invasive surgical devices is being primarily driven by the rising prevalence of chronic diseases such as cancer, cardiovascular disorders, increasing technological advancement in surgical devices, and an increase in product development activities among the key market players globally.